Drugs / mRNA-1273.211
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04889209 | May 2021 → Jun 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT04927065 | May 2021 → Nov 2023 | COVID-19 | ModernaTX, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-04-19 | ModernaTX, Inc. | Results Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform q4web.com ↗
A 50 µg booster dose of mRNA-1273.211 demonstrated superiority against Beta, Delta and Omicron variants of concern one month after administration. |
| 2022-01-26 | ModernaTX, Inc. | Results Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant q4web.com ↗
Additionally, Moderna announced the publication of neutralizing antibody data against the Omicron variant six months following a booster dose in The New England Journal of Medicine. |
| 2021-04-13 | ModernaTX, Inc. | Results Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day q4web.com ↗
New results from a preclinical study of the Company’s COVID-19 variant-specific vaccine candidates showed that the Company’s variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-04-19 | ModernaTX, Inc. | Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform q4web.com ↗ |
| 2022-01-26 | ModernaTX, Inc. | Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant q4web.com ↗ |
| 2021-04-13 | ModernaTX, Inc. | Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day q4web.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1273.211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04927065 ↗ |
| Route | Intramuscular | “randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273.211 (boost dose).” NCT04889209 ↗ |